Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

Original languageEnglish (US)
Pages (from-to)362-369
Number of pages8
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Volume2013
StatePublished - 2013
Externally publishedYes

Fingerprint

Fetal Hemoglobin
Hydroxyurea
Sickle Cell Anemia
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{cc27e9e009874b8cbe1b0d8cf5099f78,
title = "Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.",
abstract = "Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.",
author = "Manwani, {Deepa G.} and Frenette, {Paul S.}",
year = "2013",
language = "English (US)",
volume = "2013",
pages = "362--369",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Vaso-occlusion in sickle cell disease

T2 - pathophysiology and novel targeted therapies.

AU - Manwani, Deepa G.

AU - Frenette, Paul S.

PY - 2013

Y1 - 2013

N2 - Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

AB - Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted the important contributions of various cellular and soluble participants in the vaso-occlusive cascade. The role of these elements and the opportunities for therapeutic intervention are summarized in this review.

UR - http://www.scopus.com/inward/record.url?scp=84902435685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902435685&partnerID=8YFLogxK

M3 - Article

C2 - 24319205

AN - SCOPUS:84902435685

VL - 2013

SP - 362

EP - 369

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -